2015
DOI: 10.1002/oby.21095
|View full text |Cite
|
Sign up to set email alerts
|

Case Study: Weight loss in a patient with type 2 diabetes: Challenges of diabetes management

Abstract: minute in the clinical studies (but not blood pressure). In obesity clinical trials, 6 (0.2%) of 3384 liraglutide 3.0 mg-treated patients and none of the 1941 placebo-treated patients reported suicidal ideation and prescribers should be aware of this caution. The final safety issue is hypersensitivity and prescribers should be aware that there are rare reports of serious reactions to this protein given by injection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 1 publication
0
3
0
Order By: Relevance
“…It has been used as a short-term management of obesity (123) and is approved for short-term (up to 12 weeks) weight management. Like other sympathomimetic agents, phentermine is associated with elevations of blood pressure and heart rate and is not recommended in individuals with preexisting cardiac issues (124). A retrospective cohort study (125) found that cardiovascular disease was rare in individuals taking phentermine for 12 and 24 months, although a slight increase in heart rate was observed.…”
Section: Sympathomimeticsmentioning
confidence: 99%
“…It has been used as a short-term management of obesity (123) and is approved for short-term (up to 12 weeks) weight management. Like other sympathomimetic agents, phentermine is associated with elevations of blood pressure and heart rate and is not recommended in individuals with preexisting cardiac issues (124). A retrospective cohort study (125) found that cardiovascular disease was rare in individuals taking phentermine for 12 and 24 months, although a slight increase in heart rate was observed.…”
Section: Sympathomimeticsmentioning
confidence: 99%
“…TrkB | neurocircuitry | dorsomedial hypothalamus | energy expenditure | feeding I mpairments in energy homeostasis resulting from the compound effects of overeating and sedentary lifestyles have led to a profound increase in the rate of obesity around the world (1). Therapeutic strategies aimed at combating obesity by increasing energy expenditure or decreasing appetite have commonly failed due to counterregulatory mechanisms (2) and adverse side effects on cardiovascular physiology (3)(4)(5). To achieve safe and sustained weight loss, it will be essential to understand the mechanisms that govern and coordinate discrete physiological processes that contribute to energy homeostasis.…”
mentioning
confidence: 99%
“…Efforts to combat obesity have traditionally focused on lifestyle changes including diet and exercise; however, these strategies have met with limited success in sustaining weight loss (2,3). Additionally, therapeutic strategies aimed at increasing energy expenditure or decreasing appetite have commonly failed due to adverse side effects on cardiovascular physiology (4)(5)(6). In order to achieve safe and sustained weight loss, it will be essential to understand the mechanisms that govern and coordinate discrete physiological processes that contribute to energy homeostasis.…”
Section: Introductionmentioning
confidence: 99%